Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Glancy Binkow & Goldberg LLP announces that all persons or entities who purchased the securities of K-V Pharmaceutical Company (“K-V Pharmaceutical” or the “Company”...
Law Offices of Howard G. Smith, representing investors of K-V Pharmaceutical Company (“K-V" or the “Company”) (NYSE:KV-A) (NYSE:KV-B), has filed a class action lawsuit in the...
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Eastern District of Missouri on behalf of a...
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and enforcement of federal antitrust laws, is investigating potential wrongdoing at...
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of purchasers of the common stock of K-V Pharmaceutical Company (“K-V...
Zeldes & Haeggquist, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible violations of the federal securities laws by K-V...
K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call PR Newswire ST. LOUIS, June 13, 2011 ST. LOUIS, June 13, 2011 /PRNewswire/ -- K-V...
K-V Pharmaceutical Company Announces $200 Million Private Debt Offering PR Newswire ST. LOUIS, March 1, 2011 ST. LOUIS, March 1, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb...
KV Pharmaceutical Company Announces Delay In Conference Call and Provides Overview Of Conference Call Comments PR Newswire ST. LOUIS, Feb. 14, 2011 ST. LOUIS, Feb. 14, 2011 /PRNewswire/ -- KV...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
